CTOs on the Move

University of Vermont - College of Medicine

www.vtahec.org

 
University of Vermont - College of Medicine is a Burlington, VT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.vtahec.org
  • 1 S Prospect St
    Burlington, VT USA 05401
  • Phone: 802.656.2179

Executives

Name Title Contact Details

Similar Companies

Healthcare Resource Network

Healthcare Resource Network is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

EyeCare Services Partners

EyeCare Services Partners (ESP) provides ownership and practice management of ophthalmologic, optometric and ambulatory surgery centers nationwide. ESP offers eye care providers and ambulatory surgery center owners compelling and effective solutions for today`s constantly changing healthcare environment. Utilization of our resources and expertise eliminates the stress of practice management. We are creating the nation`s leading eyecare services company in both quality and scale by consolidating ophthalmologic and optometric practices and ambulatory surgery centers that are locally dominant and clinically differentiated. We provide a patient centric model that delivers outstanding care and quality outcomes through our providers and staff by leveraging our comprehensive array of best-in-class technology, processes and managerial infrastructure.

Systemedic Rmi Inc

Systemedic Rmi Inc is a Little Rock, AR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TruWin

TruWin, Inc. is a Canonsburg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HedgePath Pharmaceuticals

HedgePath Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer. The Company may also explore acquiring or licensing innovative therapeutics addressing unmet needs and orphan indications beyond cancer. We are focused on the development of therapies for more than one type of cancer, with initial emphasis in the U.S. market, based upon repurposing the currently marketed antifungal drug itraconazole for new indications in oncology.